Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Luis Miguel Juárez"'
Publikováno v:
Drugs in Context, Vol 9, Pp 1-15 (2020)
Therapeutic options for relapsed/refractory B-cell acute lymphoblastic leukemia have evolved in the past few years. The FDA has approved three novel therapies for this disease: inotuzumab ozogamicin (an anti-CD22 antibody–drug conjugate), blinatumo
Externí odkaz:
https://doaj.org/article/2bcd1842e3de4944a966849e55ed66c2
Publikováno v:
Drugs in Context, Vol 9, Pp 1-12 (2020)
The identification of the CD20 antigen in 1979 was the first step in what would become a therapeutic milestone opening the use of immunotherapy in hematological diseases. This protein is expressed on the surface of developing B cells, but not the ear
Externí odkaz:
https://doaj.org/article/2cbfc9397c794be4951defc1684b1475
Publikováno v:
Drugs in Context, Vol 8, Pp 1-13 (2019)
The emergence of targeted therapy for patients with hematological diseases has permanently altered the therapeutic landscape. Immunochemotherapy regimes are now more and more being replaced by targeted therapies due to superior efficacy and better sa
Externí odkaz:
https://doaj.org/article/3ef28902caec4049ad321e9731eb41eb
Autor:
Ignacio Gómez-Centurión, Rebeca Bailén, Mariana Bastos-Oreiro, Gillen Oarbeascoa, María Carmen López Fresneña, Cristina Encinas, Nieves Dorado, Eva González-Haba, María Josefa Martínez Carreño, Patricia Font Lopez, Gabriela Rodriguez Macias, José Luis Díez-Martín, María Sanjurjo, Vicente Escudero Vilaplana, María Carmen García, Mi Kwon, Javier Anguita, Luis Miguel Juárez
Publikováno v:
International Journal of Hematology
Background “Hospital-at-home” (HAH) programs have been shown to optimize resource utilization, shorten hospitalization and prevent nosocomial infection. Methods We retrospectively analysed data regarding implementation of an HAH unit for caring p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41753599a640723493b5e9a6534642b4
https://doi.org/10.1007/s12185-021-03219-2
https://doi.org/10.1007/s12185-021-03219-2
Publikováno v:
Drugs in Context, Vol 9, Pp 1-12 (2020)
Drugs in Context
Drugs in Context
The identification of the CD20 antigen in 1979 was the first step in what would become a therapeutic milestone opening the use of immunotherapy in hematological diseases. This protein is expressed on the surface of developing B cells, but not the ear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d84ee12f6ce164208ab2229240529868
https://drugsincontext.com/use-of-anti-cd20-therapy-in-follicular-and-marginal-zone-lymphoma:-a-review-of-the-literature
https://drugsincontext.com/use-of-anti-cd20-therapy-in-follicular-and-marginal-zone-lymphoma:-a-review-of-the-literature
Autor:
Jeffrey L. Wolf, María Poza, Irene Zamanillo, Natasha Bahri, Ricardo Sanchez, José María Sánchez-Pina, Thomas Martin, Sandy W. Wong, Rafael Feito Alonso, Joaquin Martinez-Lopez, Luis Miguel Juárez, Luis Collado, Cristina Encinas, Rafael Rios, Natalia Buenache, Santiago Barrio, Fatima Miras, María Teresa Cedena, Yanira Ruiz-Heredia, Nina Shah
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-4 (2021)
Journal of hematology & oncology, vol 14, iss 1
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-4 (2021)
Journal of hematology & oncology, vol 14, iss 1
The assessment of measurable residual disease (MRD) in bone marrow has proven of prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other hematologic malignancies, the use of MRD results to make clinical decisions i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b70413b5b3709a47ac8777a10647e54
https://pubmed.ncbi.nlm.nih.gov/34404440
https://pubmed.ncbi.nlm.nih.gov/34404440
Publikováno v:
Drugs in Context, Vol 8, Pp 1-13 (2019)
Drugs in Context
Drugs in Context
The emergence of targeted therapy for patients with hematological diseases has permanently altered the therapeutic landscape. Immunochemotherapy regimes are now more and more being replaced by targeted therapies due to superior efficacy and better sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8650013abdcf76eb9af1b2557132ccb6
https://doi.org/10.7573/dic.212574
https://doi.org/10.7573/dic.212574
Publikováno v:
Atlas of Genetics and Cytogenetics in Oncology and Haematology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a49bb2499da477179e6c251bf1526dc9
https://doi.org/10.4267/2042/70779
https://doi.org/10.4267/2042/70779
Publikováno v:
Annals of translational medicine. 7(Suppl 8)
Progressive multifocal leukoencephalopathy (PML) is an opportunist viral infection predominantly seen in immunosuppressed patients (most commonly in HIV cases, lymphoproliferative disorders and primary immunodeficiency) (1,2). This aggressive brain i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8448c99e9e23251778afa590c3d16e89
https://pubmed.ncbi.nlm.nih.gov/30969503
https://pubmed.ncbi.nlm.nih.gov/30969503
Publikováno v:
Atlas of Genetics and Cytogenetics in Oncology and Haematology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3bfb598a92a7b2b0dcd99eb6e1fbe16b
https://doi.org/10.4267/2042/70612
https://doi.org/10.4267/2042/70612